{
    "2021-01-22": [
        [
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)股东温州特瑞西创计划减持不超过1239万股 拟减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "温州特瑞西创",
                        "减持",
                        "1239万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：股东温州特瑞西创拟减持不超3%股份 拟减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "温州特瑞西创",
                        "减持",
                        "3%股份"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：温州特瑞西创拟减持不超过总股本3% 拟减持股份",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "温州特瑞西创",
                        "减持",
                        "总股本3%"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558)：KRAS抑制剂受理 肺癌市场潜力巨大",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "KRAS抑制剂",
                        "受理",
                        "肺癌市场",
                        "潜力巨大"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "盘点：国内在研的15款 T790M “EGFR-TKI”",
                "features": {
                    "keywords": [
                        "国内在研",
                        "T790M",
                        "EGFR-TKI"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}